BNP Paribas Financial Markets’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-26,303
| Closed | -$127K | – | 4435 |
|
|
2020
Q1 | $127K | Buy |
26,303
+20,950
| +391% | +$136K | ﹤0.01% | 3091 |
|
|
2019
Q4 | $56.9K | Sell |
5,353
-1,376
| -20% | -$13.7K | ﹤0.01% | 3579 |
|
|
2019
Q3 | $70K | Buy |
6,729
+2,479
| +58% | +$32.4K | ﹤0.01% | 3315 |
|
|
2019
Q2 | $65.1K | Sell |
4,250
-3,707
| -47% | -$53.6K | ﹤0.01% | 3266 |
|
|
2019
Q1 | $102K | Buy |
+7,957
| New | +$90K | ﹤0.01% | 3112 |
|
|
2018
Q4 | – | Sell |
-984
| Closed | -$16.3K | – | 4489 |
|
|
2018
Q3 | $16.3K | Hold |
984
| – | – | ﹤0.01% | 3502 |
|
|
2018
Q2 | $15.8K | Sell |
984
-4,590
| -82% | -$81.9K | ﹤0.01% | 3585 |
|
|
2018
Q1 | $85.3K | Sell |
5,574
-277
| -5% | -$4.32K | ﹤0.01% | 3273 |
|
|
2017
Q4 | $91.3K | Buy |
5,851
+3,534
| +153% | +$47.3K | ﹤0.01% | 3351 |
|
|
2017
Q3 | $25.7K | Sell |
2,317
-255
| -10% | -$2.4K | ﹤0.01% | 3468 |
|
|
2017
Q2 | $23.7K | Buy |
2,572
+7
| +0.3% | +$58 | ﹤0.01% | 3575 |
|
|
2017
Q1 | $21.9K | Buy |
2,565
+1,704
| +198% | +$15.5K | ﹤0.01% | 2997 |
|
|
2016
Q4 | $9.21K | Sell |
861
-271
| -24% | -$3.28K | ﹤0.01% | 3491 |
|
|
2016
Q3 | $12.3K | Buy |
1,132
+480
| +74% | +$3.9K | ﹤0.01% | 3114 |
|
|
2016
Q2 | $4.41K | Buy |
+652
| New | +$4.12K | ﹤0.01% | 3315 |
|
|
2016
Q1 | – | Sell |
-4,316
| Closed | -$27.2K | – | 3284 |
|
|
2015
Q4 | $27.2K | Buy |
4,316
+799
| +23% | +$6.48K | ﹤0.01% | 3175 |
|
|
2015
Q3 | $31.1K | Buy |
3,517
+2,217
| +171% | +$23.3K | ﹤0.01% | 3152 |
|
|
2015
Q2 | $15.3K | Buy |
1,300
+1,088
| +513% | +$15.1K | ﹤0.01% | 3208 |
|
|
2015
Q1 | $3.07K | Buy |
+212
| New | +$3.25K | ﹤0.01% | 3376 |
|
|
2014
Q4 | – | Sell |
-859
| Closed | -$10.7K | – | 3552 |
|
|
2014
Q3 | $10.7K | Buy |
+859
| New | +$10.6K | ﹤0.01% | 3552 |
|
|
2014
Q1 | – | Sell |
-118
| Closed | -$2.31K | – | 3964 |
|
|
2013
Q4 | $2.31K | Buy |
+118
| New | +$3.15K | ﹤0.01% | 3591 |
|
BNP Paribas Financial Markets's STML Position: Q2 2020 in Review
BNP Paribas Financial Markets sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 26,303 shares — an estimated $127K sold.
BNP Paribas Financial Markets first reported a position in STML in Q4 2013 and held it in 21 quarters. The position peaked at $127K in Q1 2020. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- BNP Paribas Financial Markets reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- BNP Paribas Financial Markets sold 26,303 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $127K.
- BNP Paribas Financial Markets first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 21 quarters.
- BNP Paribas Financial Markets's Stemline Therapeutics, Inc. position peaked at $127K in Q1 2020.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2020, filed 6 Aug 2020.